The study demonstrated significantly improved heart failure symptoms and estimated GFR derived from a combination of serum creatinine and serum cystatin C from 70.47 mL/min/1.73 m2 to 76.27 mL/min/1.73 m2 after a median follow-up time of 16 months after the treatment (P-value 0.006) with a trend in decreasing N-terminal pro b-type natriuretic peptide (NT-proBNP). The gene discussed is CST3; the disease is heart failure.